/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte Corporation (INCY), headquartered in Wilmington, Delaware, discovers, develops, and commercializes therapeutics for hematology/oncology, as well as inflammation and autoimmunity areas. Valued at $16.7 billion by market cap, the company follows science to find solutions for patients with unmet medical needs.
Shares of this global biopharmaceutical company have outperformed the broader market over the past year. INCY has gained 35.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 14.3%. In 2025, INCY stock is up 23.7%, surpassing the SPX’s 9% rise on a YTD basis.